Nebulized study drug before lung cancer surgery
Part of Cancer, Lungs & breathing clinical trials.
This study tests an inhaled study drug before lung cancer surgery to see if it helps. You may join if you have a new diagnosis of a common type of lung cancer and are scheduled for surgery or radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been recently diagnosed with lung adenocarcinoma or squamous cell carcinoma
- Your tumor is not recurrent and has not spread to lymph nodes or other parts of the body (multiple lung tumors are okay)
- You have had a PET/CT scan at Stephenson Cancer Center within the last 30 days
- You are able to provide informed consent and are not pregnant or a prisoner
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called IBI363 given before surgery for early-stage non-small cell lung cancer. The goal is to see if it can help shrink the tumor and improve the chances of successful surgery.
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
This trial tests a new combination of radiation, two immunotherapy drugs, and chemotherapy given before surgery for non-small-cell lung cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients with stage II-III disease that can be removed with surgery.
This trial tests a new targeted pill (zipalertinib) combined with standard chemotherapy (carboplatin and pemetrexed) before surgery for early-stage lung cancer with specific EGFR mutations. It aims to shrink the tumor and potentially improve outcomes after surgery.
This trial tests whether taking lazertinib before surgery can shrink or control EGFR-mutant lung adenocarcinoma that can be fully removed by an operation. It uses a special liquid biopsy from fluid in the lungs to confirm the EGFR mutation and guide treatment.
This trial tests a new targeted drug (SHR-A1811) combined with an immunotherapy drug (adebelimumab) before surgery for patients with early-stage, resectable lung cancer that has a specific HER2 alteration. The goal is to shrink the tumor and improve outcomes.
Hear when a new Non-small Cell Lung Cancer Stage I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.